Independent directory Public ClinicalTrials.gov records United States
Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 18, 2026, 4:13 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1033–1056 of 17,842 matching trials from the live ClinicalTrials.gov search.
Conditions
Lung Cancer, Metastatic Cancer
Interventions
3'-deoxy-3'-[18F]FLT, Single photon emission computed tomography
Other · Procedure
Lead sponsor
Barbara Ann Karmanos Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
1
States / cities
Detroit, Michigan
Conditions
Metastatic Kidney Carcinoma, Recurrent Lung Non-Small Cell Carcinoma, Stage IV Cutaneous Melanoma AJCC v6 and v7, Stage IV Renal Cell Cancer AJCC v7, Stage IV Lung Non-Small Cell Cancer AJCC v7
Interventions
Atezolizumab, Hypofractionated Radiation Therapy, Laboratory Biomarker Analysis, Nelfinavir Mesylate, Nivolumab, Pembrolizumab
Drug · Radiation · Other + 1 more
Lead sponsor
University of Washington
Other
Eligibility
18 Years and older
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
1
States / cities
Seattle, Washington
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Effect of GLP-1 Receptor Agonism After Sleeve Gastrectomy

NCT03115424
Conditions
Obesity
Interventions
Saxenda, Placebos, RYGB
Drug · Procedure
Lead sponsor
Mayo Clinic
Other
Eligibility
20 Years to 65 Years
Enrollment
46 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2024
U.S. locations
1
States / cities
Rochester, Minnesota
Conditions
Anatomic Stage IV Breast Cancer AJCC v8, Metastatic Triple-Negative Breast Carcinoma
Interventions
Radiation Therapy, Pembrolizumab, Nab-paclitaxel, Paclitaxel, Carboplatin, Gemcitabine, Biopsy, Computed Tomography, Bone Scan, Biospecimen Collection, Medical Chart Review
Radiation · Biological · Drug + 2 more
Lead sponsor
Emory University
Other
Eligibility
18 Years and older
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
1
States / cities
Atlanta, Georgia
Terminated Phase 1Phase 2 Interventional Results available

Carfilzomib and Stem Cell Transplant for Plasma Cell Myeloma

NCT01658904
Conditions
Multiple Myeloma, Leukemia, Plasma Cell
Interventions
Carfilzomib, Melphalan, Filgrastim
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years to 75 Years
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
1
States / cities
Bethesda, Maryland
Completed Not applicable Interventional Accepts healthy volunteers Results available

Pharmacotherapy and Mechanisms of Sleep Disturbance in Alcohol Dependence

NCT01014533
Conditions
Alcohol Dependence, Insomnia
Interventions
Placebo dispensed to subject., Gabapentin dispensed to subject.
Drug
Lead sponsor
Dr. Kirk Brower
Other
Eligibility
18 Years to 65 Years
Enrollment
59 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2011
U.S. locations
1
States / cities
Ann Arbor, Michigan
Conditions
Cancer Cachexia
Interventions
Eicosapentaenoic Acid
Drug
Lead sponsor
H. Lee Moffitt Cancer Center and Research Institute
Other
Eligibility
25 Years to 80 Years
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
2
States / cities
Stuart, Florida • Tampa, Florida
Conditions
Muscular Atrophy, Spinal
Interventions
Placebo, Risdiplam
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
2 Years to 25 Years
Enrollment
231 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2023
U.S. locations
2
States / cities
Palo Alto, California • New York, New York
Terminated Phase 4 Interventional Results available

Reduction in Symptomatic Esophageal Stricture Formation

NCT02039115
Conditions
Esophageal Stenosis
Interventions
prednisone, placebo
Drug
Lead sponsor
AdventHealth
Other
Eligibility
18 Years to 89 Years
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
1
States / cities
Orlando, Florida
Conditions
Non Small Cell Lung Cancer
Interventions
Pembrolizumab, Carboplatin, Paclitaxel, Pemetrexed, Nivolumab, Ipilimumab
Drug
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
18 Years to 89 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
Birmingham, Alabama
Conditions
Diabetic Chronic Kidney Disease
Interventions
GCS-100, Placebo
Drug
Lead sponsor
La Jolla Pharmaceutical Company
Industry
Eligibility
18 Years to 90 Years
Enrollment
375 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
8
States / cities
Chula Vista, California • El Centro, California • La Jolla, California + 5 more
Conditions
Solid Tumor
Interventions
PT0253, Chemotherapy Combination 1, Chemotherapy Combination 2, Chemotherapy Combination 3, Cetuximab
Drug
Lead sponsor
PAQ Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
9
States / cities
Los Angeles, California • Boston, Massachusetts • Grand Rapids, Michigan + 4 more
Conditions
Healthy
Interventions
Olomorasib
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years to 55 Years
Enrollment
120 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025
U.S. locations
2
States / cities
San Antonio, Texas • Salt Lake City, Utah
Conditions
CLL, SLL
Interventions
Ofatumumab, High-Dose Methylprednisolone, Alemtuzumab
Drug
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2017
U.S. locations
2
States / cities
Boston, Massachusetts
Conditions
Hepatitis C Virus (HCV) Infection
Interventions
Community health worker (CHW)/ registered nurse (RN) [CHW/RN], Clinic-based Standard of Care (cbSOC) Program (control group)
Behavioral
Lead sponsor
University of California, Irvine
Other
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
7
States / cities
Los Angeles, California
Conditions
Cutaneous Squamous Cell Carcinoma, Squamous Cell Carcinoma, Basal Cell Carcinoma
Interventions
Copaxone
Drug
Lead sponsor
University of Kansas Medical Center
Other
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2024
U.S. locations
3
States / cities
Fairway, Kansas • Kansas City, Kansas
Conditions
Adenocarcinoma of the Prostate
Interventions
IMC-A12 (Cixutumumab)
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older · Male only
Enrollment
41 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2013
U.S. locations
3
States / cities
San Francisco, California • Portland, Oregon • Seattle, Washington
Completed Phase 2 Interventional Results available

A Multicenter Study of NAP (AL-108) in Schizophrenia

NCT00505765
Conditions
Schizophrenia
Interventions
AL-108, Placebo
Drug
Lead sponsor
University of California, Los Angeles
Other
Eligibility
18 Years to 60 Years
Enrollment
63 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
8
States / cities
Los Angeles, California • Catonsville, Maryland • Boston, Massachusetts + 4 more
Conditions
Breast Cancer
Interventions
Bevacizumab, Standard adjuvant chemotherapy
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years and older
Enrollment
2,591 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2014
U.S. locations
44
States / cities
Huntsville, Alabama • Mobile, Alabama • Fayetteville, Arkansas + 40 more
Conditions
Solid Tumor
Interventions
BHV-1510, Cemiplimab
Drug
Lead sponsor
Biohaven Therapeutics Ltd.
Industry
Eligibility
18 Years and older
Enrollment
500 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
17
States / cities
Duarte, California • La Jolla, California • Palo Alto, California + 14 more
Completed Phase 1 Interventional Results available

ABEMA Alone or in COMBO With MK-6482

NCT04627064
Conditions
Clear Cell Renal Cell Carcinoma
Interventions
Abemaciclib, MK-6482
Drug
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
1
States / cities
Boston, Massachusetts
Conditions
Hepatic Encephalopathy
Interventions
sodium phenylacetate and sodium benzoate injection 10% / 10%, placebo solution (10% dextrose)
Drug
Lead sponsor
Amgen
Industry
Eligibility
18 Years to 75 Years
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
3
States / cities
Fresno, California • Loma Linda, California • Odessa, Texas
Conditions
Growth Hormone Deficiency
Interventions
Somatropin
Drug
Lead sponsor
Altus Pharmaceuticals
Industry
Eligibility
3 Years to 13 Years
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2009
U.S. locations
11
States / cities
Little Rock, Arkansas • Orlando, Florida • Springfield, Massachusetts + 7 more
Terminated Phase 1Phase 2 Interventional Results available

PRO-MERIT (Prostate Cancer Messenger RNA Immunotherapy)

NCT04382898
Conditions
Prostate Cancer
Interventions
BNT112, Cemiplimab
Biological · Drug
Lead sponsor
BioNTech SE
Industry
Eligibility
18 Years and older · Male only
Enrollment
75 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2024
U.S. locations
5
States / cities
Tucson, Arizona • Miami, Florida • Pittsburgh, Pennsylvania + 2 more